Coats disease and leukocoria assessment

Coats Disease

Coats disease is a rare, idiopathic, non-hereditary retinal vascular anomaly characterized by progressive aneurysmal dilatations of retinal vessels, telangiectatic capillary malformations, and massive intraretinal and subretinal lipid exudation, ultimately culminating in exudative retinal detachment.

Epidemiology & Demographics

• Gender Predilection: Strong male predominance, with approximately 80% to 85% of cases occurring in males (male-to-female ratio ~3:1 to 4:1).
• Laterality: Overwhelmingly unilateral (85% to 90%); bilateral cases are exceedingly rare and should prompt investigation for underlying systemic or genetic vitreoretinopathies (such as facioscapulohumeral muscular dystrophy [FSHD] or familial exudative vitreoretinopathy [FEVR]).
• Age of Onset: Most commonly diagnosed in young children during the first decade of life (peak age 6 to 8 years). However, a bimodal age distribution exists: an early, aggressive paediatric form, and a milder, indolent presentation diagnosed in young-to-middle-aged adults.

Cellular Pathophysiology & Vascular Malformations

The fundamental pathological defect in Coats disease is primary endothelial cell failure and loss of vascular pericytes within the retinal microvasculature:

1. Inner Blood-Retinal Barrier Breakdown: Somatic mutations in the NDP gene (Norrie disease protein / norrin) have been identified in some patients. Endothelial tight junctions disassemble, leading to catastrophic breakdown of the inner blood-retinal barrier.
2. "Lightbulb" Telangiectasias: Capillaries, venules, and arterioles undergo localized ectasia, saccular outpouchings, and fusiform aneurysmal dilatation, creating the characteristic "lightbulb" telangiectatic vessels typically located in the temporal and inferior mid-periphery.
3. Massive Lipid Exudation: The incompetent, leaky telangiectasias pour plasma constituents, cholesterol, and lipoproteins into the retina. Lipid precipitates into enormous, glistening, yellowish-white mounds in the outer plexiform layer and subretinal space, often gravitating to the fovea to form a massive subfoveal lipid plaque.
4. Exudative Retinal Detachment: Progressive accumulation of proteinaceous, amber subretinal fluid separates the neurosensory retina from the underlying RPE without any retinal tears or holes (non-rhegmatogenous, bullous serous detachment).

The Critical Differential Diagnosis: Coats Disease vs. Retinoblastoma

Differentiating Coats disease from retinoblastoma is one of the most critical life-and-death diagnostic challenges in paediatric ophthalmology. Both conditions present with leukocoria (white pupillary reflex) or strabismus in young children:

Shields Staging System & Management Paradigms in Coats Disease

The Shields classification provides a rigorous framework for staging and therapeutic intervention:

• Stage 1 (Telangiectasia only): Telangiectatic and aneurysmal vessels without intraretinal or subretinal exudation. Managed with direct argon or diode green/yellow laser photocoagulation applied to the telangiectatic vessels to obliterate abnormal flow.
• Stage 2 (Telangiectasia and exudation):
  • Stage 2A: Extrafoveal exudation. Treated with confluent focal laser photocoagulation or transscleral cryotherapy to the abnormal peripheral telangiectatic beds.
  • Stage 2B: Foveal exudation. The offending peripheral telangiectasias are aggressively ablated. Direct laser to the fovea is strictly avoided; resorption of subfoveal lipid occurs slowly after vascular leakage is controlled; the interval varies and established foveal damage can persist. Anti-VEGF can be considered selectively as an adjunct, with attention to traction/fibrosis risk; control of abnormal leaking vessels remains central.
• Stage 3 (Exudative Retinal Detachment):
  • Stage 3A: Subtotal exudative detachment (3A1: extrafoveal; 3A2: involving the fovea). Managed with transscleral cryotherapy (double freeze-thaw) to anterior telangiectasias where subretinal fluid prevents laser uptake, with anti-VEGF considered selectively as an adjunct; discuss traction/fibrosis risk and the need to treat leaking vessels.
  • Stage 3B: Total bullous exudative retinal detachment. Requires surgical intervention: external transscleral subretinal fluid drainage (via sclerotomy) or 23/25-gauge pars plana vitrectomy with internal drainage, endolaser ablation of telangiectasias, and temporary silicone oil tamponade.
• Stage 4 (Total detachment with secondary glaucoma): Closed-angle neovascular glaucoma secondary to iris rubeosis or forward displacement of the lens-iris diaphragm. Managed with cyclodestructive procedures (transscleral diode cyclophotocoagulation) or enucleation for blind, painful eyes.
• Stage 5 (End-stage): Phthisis bulbi, band keratopathy, cataracts, and complete globe disorganization. Observation or enucleation for intractable pain.